SG10201806809QA - 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders - Google Patents

1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders

Info

Publication number
SG10201806809QA
SG10201806809QA SG10201806809QA SG10201806809QA SG10201806809QA SG 10201806809Q A SG10201806809Q A SG 10201806809QA SG 10201806809Q A SG10201806809Q A SG 10201806809QA SG 10201806809Q A SG10201806809Q A SG 10201806809QA SG 10201806809Q A SG10201806809Q A SG 10201806809QA
Authority
SG
Singapore
Prior art keywords
compounds
heterocyclyl
analogs
isochromanyl
cns disorders
Prior art date
Application number
SG10201806809QA
Other languages
English (en)
Inventor
Linghong Xie
Philip Glyn Jones
Kerry L Spear
Noel Aaron Powell
Taleen G Hanania
Vadim Alexandrov
Original Assignee
Sunovion Pharmaceuticals Inc
Pgi Drug Discovery Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunovion Pharmaceuticals Inc, Pgi Drug Discovery Llc filed Critical Sunovion Pharmaceuticals Inc
Publication of SG10201806809QA publication Critical patent/SG10201806809QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201806809QA 2015-02-11 2016-02-11 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders SG10201806809QA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562115064P 2015-02-11 2015-02-11

Publications (1)

Publication Number Publication Date
SG10201806809QA true SG10201806809QA (en) 2018-09-27

Family

ID=55456908

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201806809QA SG10201806809QA (en) 2015-02-11 2016-02-11 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
SG11201706515QA SG11201706515QA (en) 2015-02-11 2016-02-11 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201706515QA SG11201706515QA (en) 2015-02-11 2016-02-11 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders

Country Status (22)

Country Link
US (4) US9856238B2 (cg-RX-API-DMAC7.html)
EP (2) EP4046995B1 (cg-RX-API-DMAC7.html)
JP (3) JP6657241B2 (cg-RX-API-DMAC7.html)
KR (1) KR102601972B1 (cg-RX-API-DMAC7.html)
CN (2) CN111925360B (cg-RX-API-DMAC7.html)
AU (1) AU2016219253C1 (cg-RX-API-DMAC7.html)
CA (1) CA2976095C (cg-RX-API-DMAC7.html)
CY (1) CY1125198T1 (cg-RX-API-DMAC7.html)
DK (1) DK3256466T3 (cg-RX-API-DMAC7.html)
EA (1) EA201791804A1 (cg-RX-API-DMAC7.html)
ES (2) ES2967643T3 (cg-RX-API-DMAC7.html)
HU (1) HUE058698T2 (cg-RX-API-DMAC7.html)
IL (1) IL253914B (cg-RX-API-DMAC7.html)
MX (2) MX392664B (cg-RX-API-DMAC7.html)
MY (1) MY188160A (cg-RX-API-DMAC7.html)
NZ (1) NZ735011A (cg-RX-API-DMAC7.html)
PH (1) PH12017501422A1 (cg-RX-API-DMAC7.html)
PL (1) PL3256466T3 (cg-RX-API-DMAC7.html)
PT (1) PT3256466T (cg-RX-API-DMAC7.html)
SG (2) SG10201806809QA (cg-RX-API-DMAC7.html)
UA (1) UA122222C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016130796A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA122222C2 (uk) * 2015-02-11 2020-10-12 Суновіон Фармасьютикалз Інк. Сполуки 1-гетероцикліл-ізохроманілу і аналоги для лікування розладів цнс
US9758529B2 (en) * 2015-02-11 2017-09-12 Sunovion Pharmaceuticals Inc. Fused dihydro-4H-pyrazolo[5,1-C][1,4]oxazinyl compounds and analogs for treating CNS disorders
BR112019001407A2 (pt) 2016-07-29 2019-07-09 Sunovion Pharmaceuticals Inc. compostos e composições e usos dos mesmos
SG10202100724UA (en) 2016-07-29 2021-03-30 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
AU2018258117A1 (en) 2017-04-24 2019-12-12 Chase Therapeutics Corporation Compositions and method for treating depression
AU2018290889B2 (en) 2017-06-30 2024-06-27 Alto Neuroscience, Inc. NK-1 antagonist compositions and methods for use in treating depression
MX2020000523A (es) 2017-08-02 2020-08-20 Sunovion Pharmaceuticals Inc Compuestos de isocromano y usos de los mismos.
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
JP7703449B2 (ja) 2019-03-14 2025-07-07 スミトモ・ファーマ・アメリカ・インコーポレイテッド イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物
US12077546B2 (en) 2021-04-10 2024-09-03 Sumitomo Pharma Co., Ltd. Bicyclic pyridine derivative

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3438995A (en) 1968-01-08 1969-04-15 Melville Sahyun Diazaheterocyclic substituted benz-oxaheterocyclic compounds
US4963568A (en) 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
US5621133A (en) 1989-05-31 1997-04-15 Deninno; Michael P. Dopamine agonists
IE73232B1 (en) * 1990-05-25 1997-05-21 Akzo Nv Isochromane derivatives
US5238939A (en) * 1990-05-25 1993-08-24 Akzo N.V. Isochromane derivatives
EP1089993B1 (en) 1998-06-30 2003-10-22 Eli Lilly And Company 5-ht1f agonists
SE9902267D0 (sv) * 1999-06-16 1999-06-16 Astra Ab New compounds
CA2465186A1 (en) * 2001-11-08 2003-05-15 Sepracor, Inc. Methods for treating depression and other cns disorders using enantiomerically enriched desmethyl- and didesmethyl-metabolites of citalopram
WO2006066756A1 (en) * 2004-12-21 2006-06-29 F. Hoffmann-La Roche Ag Chroman derivatives and uses thereof in the treatment of cns disorders
JP2008538576A (ja) 2005-04-22 2008-10-30 ワイス クロマンおよびクロメン誘導体およびその使用
KR20080090545A (ko) * 2006-01-27 2008-10-08 에프. 호프만-라 로슈 아게 Cns 장애 치료용 2-이미다졸의 용도
KR101103118B1 (ko) 2007-11-02 2012-01-04 동아제약주식회사 신규한 1,3-디히드로-5-이소벤조퓨란카르보니트릴 유도체 화합물 및 이를 함유하는 조루증 치료용 약학조성물
CN104193761B (zh) * 2009-12-04 2017-10-17 桑诺维恩药品公司 多环化合物及其使用方法
US8569339B2 (en) 2011-03-10 2013-10-29 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
AR090557A1 (es) * 2012-04-02 2014-11-19 Orion Corp DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2
WO2014106238A1 (en) * 2012-12-31 2014-07-03 Fang, Qun, Kevin Heterocyclic compounds and methods of use thereof
UA122222C2 (uk) * 2015-02-11 2020-10-12 Суновіон Фармасьютикалз Інк. Сполуки 1-гетероцикліл-ізохроманілу і аналоги для лікування розладів цнс

Also Published As

Publication number Publication date
CN111925360A (zh) 2020-11-13
US11192885B2 (en) 2021-12-07
US20180093974A1 (en) 2018-04-05
KR20170129730A (ko) 2017-11-27
MX392664B (es) 2025-03-24
PH12017501422A1 (en) 2018-03-19
DK3256466T3 (da) 2022-05-02
PT3256466T (pt) 2022-05-10
AU2016219253C1 (en) 2022-12-08
US20170001987A1 (en) 2017-01-05
JP2018505205A (ja) 2018-02-22
AU2016219253A1 (en) 2017-09-21
ES2967643T3 (es) 2024-05-03
KR102601972B1 (ko) 2023-11-13
WO2016130796A1 (en) 2016-08-18
HUE058698T2 (hu) 2022-09-28
EP4046995C0 (en) 2023-09-13
UA122222C2 (uk) 2020-10-12
ES2911910T3 (es) 2022-05-23
MX371404B (es) 2020-01-29
EP3256466B9 (en) 2022-07-27
BR112017017354A2 (pt) 2018-04-10
JP2020079282A (ja) 2020-05-28
SG11201706515QA (en) 2017-09-28
EP3256466A1 (en) 2017-12-20
CY1125198T1 (el) 2024-12-13
CN107531674A (zh) 2018-01-02
JP6657241B2 (ja) 2020-03-04
EP3256466B1 (en) 2022-04-06
CA2976095A1 (en) 2016-08-18
MY188160A (en) 2021-11-24
MX2017010363A (es) 2018-05-04
IL253914B (en) 2021-09-30
CN111925360B (zh) 2024-03-22
US9856238B2 (en) 2018-01-02
CN107531674B (zh) 2020-07-31
EP4046995B1 (en) 2023-09-13
EA201791804A1 (ru) 2018-02-28
ES2911910T9 (es) 2022-08-12
NZ735011A (en) 2023-07-28
US20220185799A1 (en) 2022-06-16
JP2022065050A (ja) 2022-04-26
US20190389845A1 (en) 2019-12-26
JP7023994B2 (ja) 2022-02-22
CA2976095C (en) 2023-10-17
PL3256466T3 (pl) 2022-05-23
AU2016219253B2 (en) 2020-10-01
US10336732B2 (en) 2019-07-02
IL253914A0 (en) 2017-10-31
EP4046995A1 (en) 2022-08-24
MX2020001157A (es) 2022-05-27

Similar Documents

Publication Publication Date Title
PH12017501422A1 (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
MX2020006599A (es) Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
PH12017501423A1 (en) Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders
MX2022012317A (es) Oxisteroles y metodos de uso de los mismos.
MX2023002004A (es) Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX390302B (es) Oxiesteroles y metodos de uso de los mismos
MX2020010690A (es) Oxiesteroles y metodos de uso de los mismos.
PH12020551014A1 (en) Amino-fluoropiperidine derivatives as kinase inhibitor
MX2016010056A (es) 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso.
PH12020551013A1 (en) Oxy-fluoropiperidine derivative as kinase inhibitor
MX2021014531A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
EP4316591A3 (en) Oxysterols and methods of use thereof
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
MX2021015942A (es) Composiciones y métodos para tratar trastornos del snc.
WO2017177004A8 (en) Tertiary amides and method of use
PH12017501876A1 (en) Pyridopyrimidones and their use as nmda receptor modulators
ZA202107777B (en) Voruciclib polymorphs and methods of making and using thereof
MX2022005024A (es) Profarmacos de fosforo de estimuladores de guanilato ciclasa soluble (sgc).
PH12019500822B1 (en) Crystalline forms of eravacycline
MX2017003458A (es) Indazol ureas y metodo de uso.
NZ748942A (en) Pyrazolylaminobenzimidazole derivatives as jak inhibitors
MX2019000608A (es) Derivados de panteteina para tratamiento de trastornos neurologicos.